EN DE
Watch Tianjin TEDA Biomedical Engineering Co Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Tianjin TEDA Biomedical Engineering Co Ltd (8189) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Tianjin TEDA Biomedical Engineering Co Ltd stock HK$0.09, price HK$0.10, that is 13.7% below the price, quality 35 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials HK · Home China · ISIN CNE1000004H7

TT Tianjin TEDA Biomedical Engineering Co Ltd logo Thin data Nov 17, 2026

Tianjin TEDA Biomedical Engineering Co Ltd

8189 · HK

Expensive (fair value 14% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Revenue last quarter +31% vs. a year ago. 
Expensive Growth (revenue 5y +6.6 %/yr in CNY) 
Fair value HK$0.0863 · Overvalued 
Quality 35/100 
Falling price (downtrend) 
Loss-making · -12.5% net margin (TTM) 
Negative free cash flow 
Trails peers (3/10) 
Narrow moat 15/100
Thin data 
⟳ CyclicalEstimateData corrected by AI research
Watch Tianjin TEDA Biomedical Engineering Co Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.6000 HK$0.0610 Fair Value HK$0.0863 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range HK$0.0610 – HK$0.6000 · fair‑value band HK$0.0647 – HK$0.1078 · the HK$0.1000 price screens above the HK$0.0863 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Tianjin TEDA Biomedical Engineering Co in your weekly email

Every Wednesday you see whether Tianjin TEDA Biomedical Engineering Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China.

Show moreShow less

It operates through Fertiliser Products, and AI health & elderly care products and services segments. The company's biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formulas.

It also involved in the provision of integrated elderly and health care; elderly equipment leasing services; elderly-related products sales; warehousing services; processing and licensing of the fertiliser products; sales of gold products for elderly customers, such as gold amulets and bracelets; sales of chips and servers supporting healthcare solutions; research and development of elderly care business; and elderly care consulting, advisory, management, and assessment services.

In addition, the company provides and licenses electroencephalography photography (EEG) diagnosis detection services and conducts EEG detection and diagnosis technology services.

Further, the company engages in the research, development, manufacture, and application of biomedical science and technology projects; regional soil resources conditioning and remediation research services; provision of soil environmental quality standards research services; development and application of AI medical large model and MaaS platform; AI life and health project expansion; and data cleaning, database, and data intelligence analysis full-process data services.

Tianjin TEDA Biomedical Engineering Company Limited was incorporated in 2000 and is headquartered in Tianjin, the People's Republic of China.

Stock analysis

Tianjin TEDA Biomedical Engineering Co Ltd (8189) currently trades at HK$0.1000, while our estimate is HK$0.0863, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.0647 (bear) to HK$0.1078 (bull), the price of HK$0.1000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Basic Materials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Tianjin TEDA Biomedical Engineering Co Ltd reported revenue of 509M CNY in FY2025 versus 476M CNY in FY2021, a compound +1.7%/yr. Reported net income was −88.5M CNY in FY2025.

Key figures

Market cap HK$209M (≈ $26.7M) Micro · P/S ratio 0.54 · Net margin −17.4% · Return on equity −141% · Return on assets (EBIT) −6.6% (5-year average) · Operating margin 5.7% · Revenue (TTM) 593M CNY · Revenue growth (YoY) +30.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (medium confidence).

What moves the price

The share trades about 74% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 12% fair-value upside, at −14%, 8189 screens richer than that median.

Fair Value

Bear HK$0.0647 Fair Value HK$0.0863 Bull HK$0.1078
Price HK$0.1000 · Downside -13.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 9
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 48
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic). Over 10 years: +0.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.9% (2020) → −4.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

8189 screens overvalued: fair value 14% below the price. Compare with Nutrien Ltd →

Compare Tianjin TEDA Biomedical Engineering Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 174 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −13.7% · Below median
Profitability
Return on assets −33.4% · Bottom 25%
Net margin (12 months) −12.5% · Bottom 25%
Operating margin (12 months) 5.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 30.8% · Top 25%

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/B 14.53× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 0.30× · Cheapest 25%
PEG 1.80× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 17
FUTURE (revenue growth)100 · sector 17
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
The Mosaic Company MOS $20.74 $28.58 +38% vs 8189
Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 ¥30.10 ¥38.01 +26% vs 8189
Qinghai Salt Lake Industry Co 000792 ¥21.88 ¥26.81 +23% vs 8189
Nutrien Ltd NTR $69.22 $83.09 +20% vs 8189
ICL Group ICL $4.33 $4.86 +12% vs 8189
Yara International ASA YAR kr 396.10 kr 424.51 +7% vs 8189
CF Industries Holdings CF $119.34 $114.88 −4% vs 8189
UPL Limited UPL ₹551.70 ₹478.29 −13% vs 8189
Yunnan Yuntianhua Co 600096 ¥26.75 ¥17.67 −34% vs 8189
Coromandel International Limited COROMANDEL ₹1,974 ₹1,129 −43% vs 8189

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tianjin TEDA Biomedical Engineering Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tianjin TEDA Biomedical Engineering Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8189

Frequently asked questions

Is Tianjin TEDA Biomedical Engineering Co Ltd (8189) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is HK$0.0863 versus a price of HK$0.1000, about 14% lower (overvalued).
What is the fair value of 8189?
Our estimate for Tianjin TEDA Biomedical Engineering Co Ltd is HK$0.0863 (as of Nov 17, 2026), built from audited fundamentals. The current price: HK$0.1000.
What is the quality score of 8189?
Tianjin TEDA Biomedical Engineering Co Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Our calculated price target is the estimate of HK$0.0863 (as of Nov 17, 2026). Cautious scenario HK$0.0647, optimistic scenario HK$0.1078. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Tianjin TEDA Biomedical Engineering Co Ltd stock forecast for 2026?
Our estimate puts fair value at HK$0.0863, about 14% lower versus a price of HK$0.1000 (overvalued). Cautious scenario HK$0.0647, optimistic scenario HK$0.1078. The calculation is refreshed regularly with new filings.
What is the revenue of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Tianjin TEDA Biomedical Engineering Co Ltd reported trailing-twelve-month revenue of about 593M CNY (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tianjin TEDA Biomedical Engineering Co Ltd it is HK$0.0863 per share (as of Nov 17, 2026), against a price of HK$0.1000.
Is Tianjin TEDA Biomedical Engineering Co Ltd stock overvalued or undervalued in 2026?
As of Nov 17, 2026, 8189 trades above its calculated fair value: price HK$0.1000, fair value HK$0.0863, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8189?
No. The price is what the market pays today (HK$0.1000); the fair value is what the company's own numbers justify (HK$0.0863). For Tianjin TEDA Biomedical Engineering Co Ltd the two are HK$0.0137 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tianjin TEDA Biomedical Engineering Co Ltd worth?
The market values Tianjin TEDA Biomedical Engineering Co Ltd at about HK$209M (market capitalisation, as of Nov 17, 2026). Per share that is HK$0.1000; our models calculate a fair value of HK$0.0863 per share.
What do the bullish and bearish scenarios say about 8189?
Our models span a range for Tianjin TEDA Biomedical Engineering Co Ltd: cautious scenario HK$0.0647, base HK$0.0863, optimistic HK$0.1078 per share (as of Nov 17, 2026, price HK$0.1000). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of 8189?
The PEG ratio of Tianjin TEDA Biomedical Engineering Co Ltd is 1.80 (P/E divided by earnings growth, as of Nov 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Balance-sheet figures for Tianjin TEDA Biomedical Engineering Co Ltd (as of Nov 17, 2026): return on equity −140.8%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 8189 from its 52-week high?
Tianjin TEDA Biomedical Engineering Co Ltd trades at HK$0.1000, about 74% below its 52-week high of HK$0.3800 and at the low of HK$0.1000 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0863 is for.
Which stocks are comparable to Tianjin TEDA Biomedical Engineering Co Ltd?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tianjin TEDA Biomedical Engineering Co Ltd stock attractive at the current price?
The data as of Nov 17, 2026: price HK$0.1000, calculated fair value HK$0.0863 (−14%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Tianjin TEDA Biomedical Engineering Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The closing price on Nov 17, 2026 was HK$0.1000. Our estimate is HK$0.0863, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tianjin TEDA Biomedical Engineering Co Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Tianjin TEDA Biomedical Engineering Co Ltd

How large is the market capitalisation of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The market capitalisation of Tianjin TEDA Biomedical Engineering Co Ltd is HK$209M (≈ $26.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The price-to-sales ratio of Tianjin TEDA Biomedical Engineering Co Ltd is 0.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The net margin of Tianjin TEDA Biomedical Engineering Co Ltd is −17.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The return on equity (ROE) of Tianjin TEDA Biomedical Engineering Co Ltd is −141% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
On an EBIT basis the return on assets of Tianjin TEDA Biomedical Engineering Co Ltd is −6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The operating margin of Tianjin TEDA Biomedical Engineering Co Ltd is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Revenue at Tianjin TEDA Biomedical Engineering Co Ltd is growing 30.8% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Earnings per share at Tianjin TEDA Biomedical Engineering Co Ltd are growing 225% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tianjin TEDA Biomedical Engineering Co Ltd (8189) generate?
The free cash flow of Tianjin TEDA Biomedical Engineering Co Ltd is −62.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tianjin TEDA Biomedical Engineering Co Ltd (8189) carry?
The net debt of Tianjin TEDA Biomedical Engineering Co Ltd is 43.5M CNY (balance sheet 30 Jun 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tianjin TEDA Biomedical Engineering Co Ltd in the live analysis

One click puts Tianjin TEDA Biomedical Engineering Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.